AHRQ Director Defends U.S. Preventive Services Task Force
This article was originally published in The Gray Sheet
Amid wide public outcry over new advice against routine screening for prostate cancer with prostate-specific antigen blood tests, Agency for Healthcare Research and Quality Director Carolyn Clancy is defending both the draft recommendations and the group that issued them, the U.S. Preventive Services Task Force.
You may also be interested in...
Consensus document issued on transcatheter heart valves. Boston Scientific launches Asia-Pacific organization. More news briefs.
Overdiagnosis and overtreatment of prostate cancers that result from screening with prostate-specific antigen tests highlight the need for research on new diagnostics technologies, suggests a new draft statement from the U.S. Preventive Services Task Force.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.